Table 3. Open in new tab Time-Dependent...

			Crude HR	Adjusted HR^a
SSRI, cDDD
<28	21,923	41.05	1.00	Reference		1.00	Reference
28–83	8631	16.16	0.88	0.78	0.99	0.0367	0.97	0.86	1.10	0.6465
≥84	22,858	42.8	0.56	0.50	0.63	<0.0001	0.64	0.57	0.71	<0.0001
SNRI, cDDD
<28	46,638	87.32	1.00	Reference		1.00	Reference
28–83	2338	4.38	0.65	0.46	0.92	0.0138	0.81	0.57	1.14	0.2182
≥84	4436	8.31	0.47	0.35	0.64	<0.0001	0.59	0.44	0.80	0.0005
NDRI, cDDD
<28	50,894	95.29	1.00	Reference		1.00	Reference
28–83	1170	2.19	0.43	0.23	0.83	0.0121	0.56	0.29	1.08	0.0855
≥84	1348	2.52	0.15	0.05	0.47	0.0011	0.20	0.07	0.63	0.0056
Mirtazapine, cDDD
<28	47,322	88.6	1.00	Reference		1.00	Reference
28–83	2276	4.26	0.96	0.70	1.30	0.7724	1.01	0.75	1.38	0.9282
≥84	3814	7.14	0.59	0.44	0.80	0.0008	0.60	0.45	0.82	0.0011
Tricyclic/tetracyclic ATDs, cDDD
<28	46,144	86.39	1.00	Reference		1.00	Reference
28–83	3728	6.98	1.04	0.87	1.25	0.681	0.89	0.75	1.07	0.2314
≥84	3540	6.63	0.78	0.58	1.04	0.0886	0.73	0.54	0.97	0.0311
SARI (trazodone), cDDD
<28	45,344	84.89	1.00	Reference		1.00	Reference
28–83	4088	7.65	0.76	0.63	0.92	0.004	0.80	0.66	0.96	0.0189
≥84	3980	7.45	0.42	0.24	0.75	0.0029	0.52	0.29	0.91	0.0230
RIMA (moclobemide), cDDD
<28	51,838	97.05	1.00	Reference		1.00	Reference
28–83	673	1.26	2.01	1.47	2.76	<0.0001	1.91	1.39	2.61	<0.0001
≥84	901	1.69	1.69	1.25	2.29	0.0006	1.48	1.09	1.99	0.0111

Crude HR

Adjusted HR^a

95% CI

P Value

95% CI

P Value

SSRI, cDDD

<28

21,923

41.05

1.00

Reference

1.00

Reference

28–83

8631

16.16

0.88

0.78

0.99

0.0367

0.97

0.86

1.10

0.6465

≥84

22,858

42.8

0.56

0.50

0.63

<0.0001

0.64

0.57

0.71

<0.0001

SNRI, cDDD

<28

46,638

87.32

1.00

Reference

1.00

Reference

28–83

2338

4.38

0.65

0.46

0.92

0.0138

0.81

0.57

1.14

0.2182

≥84

4436

8.31

0.47

0.35

0.64

<0.0001

0.59

0.44

0.80

0.0005

NDRI, cDDD

<28

50,894

95.29

1.00

Reference

1.00

Reference

28–83

1170

2.19

0.43

0.23

0.83

0.0121

0.56

0.29

1.08

0.0855

≥84

1348

2.52

0.15

0.05

0.47

0.0011

0.20

0.07

0.63

0.0056

Mirtazapine, cDDD

<28

47,322

88.6

1.00

Reference

1.00

Reference

28–83

2276

4.26

0.96

0.70

1.30

0.7724

1.01

0.75

1.38

0.9282

≥84

3814

7.14

0.59

0.44

0.80

0.0008

0.60

0.45

0.82

0.0011

Tricyclic/tetracyclic ATDs, cDDD

<28

46,144

86.39

1.00

Reference

1.00

Reference

28–83

3728

6.98

1.04

0.87

1.25

0.681

0.89

0.75

1.07

0.2314

≥84

3540

6.63

0.78

0.58

1.04

0.0886

0.73

0.54

0.97

0.0311

SARI (trazodone), cDDD

<28

45,344

84.89

1.00

Reference

1.00

Reference

28–83

4088

7.65

0.76

0.63

0.92

0.004

0.80

0.66

0.96

0.0189

≥84

3980

7.45

0.42

0.24

0.75

0.0029

0.52

0.29

0.91

0.0230

RIMA (moclobemide), cDDD

<28

51,838

97.05

1.00

Reference

1.00

Reference

28–83

673

1.26

2.01

1.47

2.76

<0.0001

1.91

1.39

2.61

<0.0001

≥84

901

1.69

1.25

2.29

0.0006

1.48

1.09

1.99

0.0111

			Crude HR	Adjusted HR^a
SSRI, cDDD
<28	21,923	41.05	1.00	Reference		1.00	Reference
28–83	8631	16.16	0.88	0.78	0.99	0.0367	0.97	0.86	1.10	0.6465
≥84	22,858	42.8	0.56	0.50	0.63	<0.0001	0.64	0.57	0.71	<0.0001
SNRI, cDDD
<28	46,638	87.32	1.00	Reference		1.00	Reference
28–83	2338	4.38	0.65	0.46	0.92	0.0138	0.81	0.57	1.14	0.2182
≥84	4436	8.31	0.47	0.35	0.64	<0.0001	0.59	0.44	0.80	0.0005
NDRI, cDDD
<28	50,894	95.29	1.00	Reference		1.00	Reference
28–83	1170	2.19	0.43	0.23	0.83	0.0121	0.56	0.29	1.08	0.0855
≥84	1348	2.52	0.15	0.05	0.47	0.0011	0.20	0.07	0.63	0.0056
Mirtazapine, cDDD
<28	47,322	88.6	1.00	Reference		1.00	Reference
28–83	2276	4.26	0.96	0.70	1.30	0.7724	1.01	0.75	1.38	0.9282
≥84	3814	7.14	0.59	0.44	0.80	0.0008	0.60	0.45	0.82	0.0011
Tricyclic/tetracyclic ATDs, cDDD
<28	46,144	86.39	1.00	Reference		1.00	Reference
28–83	3728	6.98	1.04	0.87	1.25	0.681	0.89	0.75	1.07	0.2314
≥84	3540	6.63	0.78	0.58	1.04	0.0886	0.73	0.54	0.97	0.0311
SARI (trazodone), cDDD
<28	45,344	84.89	1.00	Reference		1.00	Reference
28–83	4088	7.65	0.76	0.63	0.92	0.004	0.80	0.66	0.96	0.0189
≥84	3980	7.45	0.42	0.24	0.75	0.0029	0.52	0.29	0.91	0.0230
RIMA (moclobemide), cDDD
<28	51,838	97.05	1.00	Reference		1.00	Reference
28–83	673	1.26	2.01	1.47	2.76	<0.0001	1.91	1.39	2.61	<0.0001
≥84	901	1.69	1.69	1.25	2.29	0.0006	1.48	1.09	1.99	0.0111

Table 3.

Open in new tab

Time-Dependent Cox Regression Analysis of Mortality in Patients With DM and Depressive Disorder: Specific ATD Subgroup Analysis

			Crude HR				Adjusted HR^a
	N	%	HR	95% CI		P Value	HR	95% CI		P Value
SSRI, cDDD
<28	21,923	41.05	1.00	Reference			1.00	Reference
28–83	8631	16.16	0.88	0.78	0.99	0.0367	0.97	0.86	1.10	0.6465
≥84	22,858	42.8	0.56	0.50	0.63	<0.0001	0.64	0.57	0.71	<0.0001
SNRI, cDDD
<28	46,638	87.32	1.00	Reference			1.00	Reference
28–83	2338	4.38	0.65	0.46	0.92	0.0138	0.81	0.57	1.14	0.2182
≥84	4436	8.31	0.47	0.35	0.64	<0.0001	0.59	0.44	0.80	0.0005
NDRI, cDDD
<28	50,894	95.29	1.00	Reference			1.00	Reference
28–83	1170	2.19	0.43	0.23	0.83	0.0121	0.56	0.29	1.08	0.0855
≥84	1348	2.52	0.15	0.05	0.47	0.0011	0.20	0.07	0.63	0.0056
Mirtazapine, cDDD
<28	47,322	88.6	1.00	Reference			1.00	Reference
28–83	2276	4.26	0.96	0.70	1.30	0.7724	1.01	0.75	1.38	0.9282
≥84	3814	7.14	0.59	0.44	0.80	0.0008	0.60	0.45	0.82	0.0011
Tricyclic/tetracyclic ATDs, cDDD
<28	46,144	86.39	1.00	Reference			1.00	Reference
28–83	3728	6.98	1.04	0.87	1.25	0.681	0.89	0.75	1.07	0.2314
≥84	3540	6.63	0.78	0.58	1.04	0.0886	0.73	0.54	0.97	0.0311
SARI (trazodone), cDDD
<28	45,344	84.89	1.00	Reference			1.00	Reference
28–83	4088	7.65	0.76	0.63	0.92	0.004	0.80	0.66	0.96	0.0189
≥84	3980	7.45	0.42	0.24	0.75	0.0029	0.52	0.29	0.91	0.0230
RIMA (moclobemide), cDDD
<28	51,838	97.05	1.00	Reference			1.00	Reference
28–83	673	1.26	2.01	1.47	2.76	<0.0001	1.91	1.39	2.61	<0.0001
≥84	901	1.69	1.69	1.25	2.29	0.0006	1.48	1.09	1.99	0.0111

			Crude HR				Adjusted HR^a
	N	%	HR	95% CI		P Value	HR	95% CI		P Value
SSRI, cDDD
<28	21,923	41.05	1.00	Reference			1.00	Reference
28–83	8631	16.16	0.88	0.78	0.99	0.0367	0.97	0.86	1.10	0.6465
≥84	22,858	42.8	0.56	0.50	0.63	<0.0001	0.64	0.57	0.71	<0.0001
SNRI, cDDD
<28	46,638	87.32	1.00	Reference			1.00	Reference
28–83	2338	4.38	0.65	0.46	0.92	0.0138	0.81	0.57	1.14	0.2182
≥84	4436	8.31	0.47	0.35	0.64	<0.0001	0.59	0.44	0.80	0.0005
NDRI, cDDD
<28	50,894	95.29	1.00	Reference			1.00	Reference
28–83	1170	2.19	0.43	0.23	0.83	0.0121	0.56	0.29	1.08	0.0855
≥84	1348	2.52	0.15	0.05	0.47	0.0011	0.20	0.07	0.63	0.0056
Mirtazapine, cDDD
<28	47,322	88.6	1.00	Reference			1.00	Reference
28–83	2276	4.26	0.96	0.70	1.30	0.7724	1.01	0.75	1.38	0.9282
≥84	3814	7.14	0.59	0.44	0.80	0.0008	0.60	0.45	0.82	0.0011
Tricyclic/tetracyclic ATDs, cDDD
<28	46,144	86.39	1.00	Reference			1.00	Reference
28–83	3728	6.98	1.04	0.87	1.25	0.681	0.89	0.75	1.07	0.2314
≥84	3540	6.63	0.78	0.58	1.04	0.0886	0.73	0.54	0.97	0.0311
SARI (trazodone), cDDD
<28	45,344	84.89	1.00	Reference			1.00	Reference
28–83	4088	7.65	0.76	0.63	0.92	0.004	0.80	0.66	0.96	0.0189
≥84	3980	7.45	0.42	0.24	0.75	0.0029	0.52	0.29	0.91	0.0230
RIMA (moclobemide), cDDD
<28	51,838	97.05	1.00	Reference			1.00	Reference
28–83	673	1.26	2.01	1.47	2.76	<0.0001	1.91	1.39	2.61	<0.0001
≥84	901	1.69	1.69	1.25	2.29	0.0006	1.48	1.09	1.99	0.0111

Abbreviation: SARI, serotonin antagonist and reuptake inhibitor.

Adjusted for seven types of ATDs, age, sex, urbanization, income, comorbidities, and adapted Diabetes Complications Severity Index.

This Feature Is Available To Subscribers Only